Refractory hairy cell leukemia
diseaseOn this page
Also known as hairy cell leukemia, refractory
Summary
Refractory hairy cell leukemia (MONDO:0004110) is a cancer and 57 clinical trials. Top therapeutic interventions include fludarabine phosphate, foscarnet, and dexrazoxane. A subtype of refractory hematologic cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 57
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | refractory hairy cell leukemia |
| Mondo ID | MONDO:0004110 |
| DOID | DOID:711 |
| NCIT | C8030 |
| UMLS | C4551546 |
| MedGen | 1639342 |
| GARD | 0023830 |
| Is cancer (heuristic) | yes |
Also known as: hairy cell leukemia, refractory · refractory hairy cell leukemia
Disease family
This is a subtype of refractory hematologic cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › refractory hematologic cancer › refractory hairy cell leukemia
Related subtypes (5): refractory precursor T-lymphoblastic lymphoma/leukemia, refractory plasma cell neoplasm, refractory anemia with excess blasts in transformation, myelodysplastic syndrome with multilineage dysplasia, refractory cytopenia of childhood
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 57.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 19 |
| PHASE2 | 16 |
| Not specified | 13 |
| PHASE1/PHASE2 | 7 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00799461 | PHASE3 | COMPLETED | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
| NCT06965114 | PHASE1/PHASE2 | RECRUITING | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia |
| NCT00006251 | PHASE1/PHASE2 | COMPLETED | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
| NCT00040846 | PHASE2 | COMPLETED | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
| NCT00078858 | PHASE1/PHASE2 | COMPLETED | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
| NCT00089011 | PHASE2 | COMPLETED | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
| NCT00089076 | PHASE1/PHASE2 | TERMINATED | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma |
| NCT00118352 | PHASE2 | COMPLETED | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
| NCT00387426 | PHASE2 | TERMINATED | Sunitinib in Treating Patients With Idiopathic Myelofibrosis |
| NCT00489203 | PHASE2 | COMPLETED | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
| NCT00795769 | PHASE2 | COMPLETED | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
| NCT00867529 | PHASE2 | COMPLETED | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
| NCT01159067 | PHASE2 | TERMINATED | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload |
| NCT01258998 | PHASE2 | COMPLETED | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
| NCT01326702 | PHASE1/PHASE2 | COMPLETED | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
| NCT01384513 | PHASE2 | COMPLETED | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
| NCT01419795 | PHASE2 | TERMINATED | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant |
| NCT01529827 | PHASE2 | COMPLETED | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| NCT01652014 | PHASE2 | WITHDRAWN | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies |
| NCT01789255 | PHASE2 | COMPLETED | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
| NCT01805037 | PHASE1/PHASE2 | TERMINATED | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
| NCT01839916 | PHASE2 | COMPLETED | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| NCT02281279 | PHASE1/PHASE2 | WITHDRAWN | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma |
| NCT05537766 | PHASE2 | TERMINATED | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies |
| NCT01815749 | PHASE1 | ACTIVE_NOT_RECRUITING | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma |
| NCT00025415 | PHASE1 | COMPLETED | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
| NCT00058227 | PHASE1 | COMPLETED | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma |
| NCT00101205 | PHASE1 | TERMINATED | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
| NCT00458731 | PHASE1 | COMPLETED | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
| NCT00608361 | PHASE1 | COMPLETED | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
| NCT00890747 | PHASE1 | COMPLETED | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
| NCT00933985 | PHASE1 | TERMINATED | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia |
| NCT01231919 | PHASE1 | COMPLETED | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
| NCT01254578 | PHASE1 | COMPLETED | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
| NCT01567709 | PHASE1 | COMPLETED | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
| NCT01588015 | PHASE1 | COMPLETED | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
| NCT01678443 | PHASE1 | TERMINATED | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
| NCT01748721 | PHASE1 | COMPLETED | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
| NCT01769222 | PHASE1 | TERMINATED | Ipilimumab and Local Radiation for Selected Solid Tumors |
| NCT02109224 | PHASE1 | TERMINATED | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUDARABINE PHOSPHATE | 4 | 12 |
| FOSCARNET | 4 | 4 |
| DEXRAZOXANE | 4 | 3 |
| ALEMTUZUMAB | 4 | 2 |
| BENDAMUSTINE HYDROCHLORIDE | 4 | 2 |
| BECLOMETHASONE DIPROPIONATE | 4 | 1 |
| BRENTUXIMAB VEDOTIN | 4 | 1 |
| BREXUCABTAGENE AUTOLEUCEL | 4 | 1 |
| CLADRIBINE | 4 | 1 |
| DEFERASIROX | 4 | 1 |
| DOXORUBICIN HYDROCHLORIDE | 4 | 1 |
| GANCICLOVIR | 4 | 1 |
| IPILIMUMAB | 4 | 1 |
| LITHIUM CARBONATE | 4 | 1 |
| MOXETUMOMAB PASUDOTOX | 4 | 1 |
| PALIFERMIN | 4 | 1 |
| RANITIDINE | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| TOVORAFENIB | 4 | 1 |
| VALGANCICLOVIR | 4 | 1 |
| ALVOCIDIB | 3 | 3 |
| VELIPARIB | 3 | 2 |
| 6-O-BENZYLGUANINE | 3 | 1 |
| ALISERTIB | 3 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| CPI 613 | 3 | 1 |
| OBATOCLAX MESYLATE | 3 | 1 |
| FLOTETUZUMAB | 2 | 1 |
| CHEMBL3109278 | 0 | 1 |
Related Atlas pages
- Drugs: Fludarabine Phosphate, Foscarnet, Dexrazoxane, Alemtuzumab, Bendamustine, Beclomethasone Dipropionate, Brentuximab Vedotin, Brexucabtagene Autoleucel, Cladribine, Deferasirox, Doxorubicin, Ganciclovir, Ipilimumab, Lithium Carbonate, Moxetumomab Pasudotox, Palifermin, Ranitidine, Romidepsin, Sunitinib Malate, Tovorafenib, Valganciclovir, Alvocidib, Veliparib, 6-O-BENZYLGUANINE, Alisertib, Cediranib, CPI 613, Obatoclax